Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists launch global study to unlock secrets of male breast cancer

NCT ID NCT01101425

Knowledge-focused Sponsor: European Organisation for Research and Treatment of Cancer - EORTC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study collects medical information and tumor samples from 200 men with breast cancer to better understand the disease. Researchers will analyze patient characteristics, treatments, and outcomes over time. The goal is to learn more about male breast cancer, which is rare and not well understood.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a better understanding of male breast cancer and potentially improve treatment approaches for men.
What could go wrong
This is an observational study, not a treatment trial. It will not directly test any new therapy, and results may take years to influence care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Start date

Dec 2010

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Retrospective part: males with histologically proven invasive breast carcinoma diagnosed since 1990 to 2010. Prospective part: all men, with histologically proven invasive breast cancer, newly presenting at the center irrespective of the stage of disease, initial diagnosis date or treatment received.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Retrospective part (closed to patients registration): * Men with histologically proven invasive breast carcinoma diagnosed since 1990 to 2010. * A FFPE tissue sample from the primary tumor (e.g. biopsy or surgery) is mandatory Prospective part: * All men, with histologically proven invasive breast cancer, newly presenting at the center irrespective of the stage of disease, initial diagnosis date or treatment received. * patients cannot be registered in both the retrospective and protective parts of the study * patients who newly present at the center in the 3 months prior to center activation are still eligible as long as they were not previously included in the retrospective part of the study * Before patient registration, written informed consent must be obtained according to ICH/GCP, and national/local regulations. * Collection of left-over FFPE and frozen tumor samples as well as blood is optional. Both parts: * Concomitant DCIS or LCIS are allowed only if invasive cancer is present. * Patients should be 18 years or over at the time of diagnosis. * The study will accept all stages of disease (e.g. early BC, locally advanced and metastatic disease) independent of the treatment received. Patients with past or concurrent other malignancies are eligible.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm male breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer

Contacts and locations

Locations

  • AZ Damiaan - Campus Sint-Jozef

    Ostend, Belgium

  • Agioi Anargiroi Hospital

    Kifissia, Greece

  • Ain Shams University Hospital

    Cairo, Egypt

  • Alexandra Hospital

    Athens, Greece

  • Aretaieio Hospital

    Athens, Greece

  • BOOG

    Amsterdam, Netherlands

  • Baylor College - Ucop

    Houston, Texas, United States

  • Baylor college of Medicine

    Houston, Texas, 77030, United States

  • Beatson West of Scotland Cancer Centre

    Glasgow, United Kingdom

  • Beaumont Hospital

    Dublin, Ireland

  • CHU St Pierre

    Brussels, Belgium

  • CHU Ucl Namu - Clinique Sainte Elisabeth

    Namur, Belgium

  • Cantonal Hospital Liestal

    Liestal, Switzerland

  • Centre Hospitalier Universitaire Vaudois

    Lausanne, Switzerland

  • Centro Regional Integrado de Oncologia

    Fortaleza, 60366-045, Brazil

  • Centro de Pesquisas Clinicas em Oncologia

    Porto Alegre, 90610 000, Brazil

  • Champalimaud Cancer Center

    Lisbon, Portugal

  • Cheltenham General Hospital

    Cheltenham, United Kingdom

  • City Hospital

    Birmingham, United Kingdom

  • Cliniques Universitaires Saint-Luc

    Brussels, 1200, Belgium

  • Cliniques Universitaires St. Luc

    Brussels, Belgium

  • Cork University Hospital

    Cork, Ireland

  • Crosshouse Hospital

    Kilmarnock, United Kingdom

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02115-5450, United States

  • Duke University Medical Center

    Durham, North Carolina, 27710, United States

  • Eastbourne District General Hospital

    Eastbourne, United Kingdom

  • Forth Valley Royal Hospital

    Larbert, United Kingdom

  • Fred Hutchison Seattle Cancer Care Alliance

    Seattle, Washington, 98109-1023, United States

  • General Hospital of Air Force

    Athens, Greece

  • General University Hospital Papageorgiou

    Thessaloniki, Greece

  • Georgetown Lombardi Comprehensive Cancer Center

    Washington D.C., District of Columbia, 20007, United States

  • Hippokration General Hospital Of Athens

    Athens, Greece

  • Hopital De Jolimont

    Haine-Saint-Paul, Belgium

  • Hopital Universitaire Brugmann

    Brussels, Belgium

  • Hopital de Sion

    Sion, Switzerland

  • Hospital General Vall D'Hebron

    Barcelona, Spain

  • Hospital Universitario 12 De Octubre

    Madrid, Spain

  • Hygeia Hospital

    Athens, Greece

  • IASO general hospital

    Athens, Greece

  • Indiana University Medical Center

    Indianapolis, Indiana, 46202-5264, United States

  • Inselspital

    Bern, Switzerland

  • Institut Jules Bordet

    Brussels, Belgium

  • Institute of Oncology and Radiology

    Belgrade, 11000, Serbia

  • Instituto De Enfermedades Neoplasicas

    Lima, Peru

  • Instituto Nacional De Cancerologia

    México, Mexico

  • Instituto Portugues De Oncologia - Centro Do Porto

    Porto, Portugal

  • Johns Hopkins University

    Baltimore, Maryland, 21287, United States

  • Johns Hopkins University CRB1

    Baltimore, Maryland, 21287, United States

  • Kantonales Spital Herisau

    Herisau, Switzerland

  • Kantonsspital Baden

    Baden, Switzerland

  • Kantonsspital St Gallen

    Sankt Gallen, Switzerland

  • Kantonsspital Winterthur

    Winterthur, Switzerland

  • LLandough Hospital

    Cardiff, United Kingdom

  • Leighton Hospital

    Crewe, United Kingdom

  • Luzerner Kantonsspital

    Lucerne, Switzerland

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Maria Sklodowska-Curie Memorial Cancer Centre

    Warsaw, Poland

  • Mater Misericordia Hospital

    Dublin, Ireland

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

  • Medical University Of Gdansk

    Gdansk, Poland

  • Memorial Sloan-Kettering Cancer Center - Memorial hospital

    New York, New York, 10065, United States

  • New Victoria Hospital

    Glasgow, United Kingdom

  • Ospedale Beata Vergine

    Mendrisio, Switzerland

  • Queen Margaret Hospital

    Dunfermline, United Kingdom

  • Radio-Onkologie Berner Oberland AG

    Thun, Switzerland

  • Royal Alexandra Hospital

    Paisley, United Kingdom

  • Royal Liverpool University Hospital

    Liverpool, United Kingdom

  • Royal Sussex County Hospital

    Brighton, United Kingdom

  • Sonnenhofklinik Engeriedspital

    Bern, Switzerland

  • Spitalzentrum Biel

    Biel, Switzerland

  • St. James'S Hospital

    Dublin, Ireland

  • St. Vincent'S Hospital

    Dublin, Ireland

  • Swedish Association of Breast Oncologists

    Gothenburg, Sweden

  • The Great Western Hospital

    Swindon, United Kingdom

  • Thermi Clinic

    Thessaloniki, Greece

  • UCSF University of California San Francisco Medical Center-Mount Zion

    San Francisco, California, 94115, United States

  • UZ Leuven

    Leuven, Belgium

  • UniversitaetsSpital Zurich

    Zurich, Switzerland

  • Universitaetsspital Basel

    Basel, Switzerland

  • Universitair Ziekenhuis Antwerpen

    Edegem, Belgium

  • University General Hospital Heraklion

    Heraklion, Greece

  • University Hospital of North Tees

    Stockton-on-Tees, United Kingdom

  • University Of Alabama Comprehensive Cancer Cente

    Birmingham, Alabama, 35294, United States

  • University Of Alabama Comprehensive Cancer Center

    Birmingham, Alabama, 35294, United States

  • University of Chicago Medicine

    Chicago, Illinois, 60637-1470, United States

  • University of Michigan

    Ann Arbor, Michigan, 48109-5912, United States

  • Waterford Regional Hospital

    Waterford, Ireland

  • Western General Hospital

    Edinburgh, United Kingdom

  • Wishaw General Hospital

    Wishaw, United Kingdom

  • Worthing Hospital

    Worthing, West Sussex, United Kingdom

  • ZNA Jan Palfijn

    Merksem, Belgium

  • ZNA Middelheim

    Antwerp, Belgium

  • ZeTuP St.Gallen

    Sankt Gallen, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.